As can be imagined, the business was in the front lines during the Covid-related sell-off and, although the recovery has taken place, the market continues to significantly discount the business based on the prospects of continued lockdowns. Especially given a significant portion of her revenues come from the food service and QSRs (Quick Service Restaurants). However, management has been gaining momentum in inventory reductions and further streamlining of the business.
Author: Sid Ruttala
In terms of catalysts for the future, the business is focusing on specific niches including the premium market as well as private label product innovation. ING’s divestment of non-core assets, most recently its dairy feed supply business, is a good move in our opinion. The most important metric in our view are the margins, which have continued to increase with gross margins at 23.4% (compared to 19.6% in 2020). With that, let’s get to the numbers.
Revenue was up 5.5% to $2.3bn, EBITDA up 15.8% to $208m, NPAT up 26.9% to $100m AUD (this takes into account the change in accounting regulations, i.e. pre-AASB 16). Arriving at the juicy and all important part, cash flow conversion continues to be a stellar 102%. What is also pleasing to see is the 3-9 month forward cover when it comes to feed, with the likely continued volatility in both soy and wheat prices as well as the recent gyrations of the AUD.
So, why does it make sense?
Firstly, management has continued to maintain discipline in its balance sheet management. This business has deleveraged to around 1.2x from 1.8x and, with the business churning out great cash flows, we should continue to see reasonable dividends and dividend growth in future. ING’s agreement with WOW looks set to be renewed though we would like to see the finer details before making further comment.
Returning to our thesis around inflation, Inghams could also be seen as a hedge given its strategy to optimise the core and cost-outs (i.e. higher margins).
Red Flags & Risks: The biggest risk continues to be further disruption as a result of Covid, not only to the domestic market but also broader supply chain and export markets. Higher feed costs and biosecurity issues could potentially have disproportionate long-term impacts.
Dividend Yield: At current prices, ~4% with expectations of high single digit growth on an annualised basis.
Monadelphous Group (MND.ASX)
For those of you that have been tuning in recently, it may be obvious that we’re onto a thematic here. That is, businesses and industries in defensive sectors and/or those that are likely to be solid inflation hedges. Having acknowledged that, let’s get to another business that should see substantial tailwinds despite what the recent price action in the spot market may suggest. To summarise MND very quickly, they operate across two verticals: engineering construction and maintenance/industrial services within the resources and energy sectors. Yes, the business has started to diversify revenue streams into water, power and marine infrastructure to deal with the cyclical nature of the mining industry but as it currently stands over 73% of revenues are tied to the fortunes of the iron ore industry.
This is one business that has never quite recovered from the Covid related sell off – not yet recovering to the $16+ mark it was trading at in February 2020 – despite the recovery in spot prices and we feel that the market has overlooked the potential for continued growth. Before proceeding further a disclaimer that, despite the sell-off in ore prices from a peak of $222 USD/T to $156 USD/T at the time of writing, we remain long-term bulls when it comes to the price given the infrastructure pipeline globally as governments continue to spend in order to resuscitate nascent aggregate demand. It must also be remembered that even at these prices, it still remains a viable proposition for businesses to place additional capex (which is arguably what matters for MND). If anything, the tight labor market and wage inflation across the resources sector broadly is an indication that the sector continues to expand. Combined with our thesis around an oil price recovery to approximately $80 USD/barrel given supply constraints in US shale production, we believe that any turbulence in MND’s revenue streams should be compensated by continued recovery in the business’ energy sector exposure.
Before proceeding further, the numbers. Revenue up 18% to $1.953bn. Of this, the outperformer (as one could guess) was the engineering and construction division with a stellar 51% increase on pcp. Basis. EBITDA was up 18% to $108m and the all important NPAT was up 29% to $47.1m AUD. Of concern was the decline in maintenance and industrial services revenue by 7%. Nevertheless, going forward the company has secured a pipeline of $470m in renewals and extensions as well as a significant $100m in new contracts in oil and gas. As that particular market recovers we should see momentum building.
Ichthys Project Onshore LNG Facilities – MEC 2 Package – Bladin Point, Darwin
Source: monadelphous.com.au
So, why does it make sense?
Despite the jitters caused by the sell-off in ore prices, it must be remembered that the business is not as directly impacted given the contracted nature of the revenues and, with a continued recovery in crude, we should see substantial tailwinds feed on through for the business. MND continues to be pleasingly disciplined and targeted in securing new contracts. Should we be correct in our prediction of a secular bull cycle in commodities broadly, the business should continue to benefit substantially while not being as exposed to the gyrations of the spot markets (in terms of revenue streams).
Red Flags & Risks: The biggest risks for the company are centred in project delays and continued volatility in commodity prices. The business also operates in a rather competitive backdrop and investors have to pay particular attention to contract growth and retention.
Dividend Yield: 4.3%
Sidenote: Telstra (TLS.ASX)
Finally, briefly revisiting Telstra. We know many of our readers are or have been holders and I have previously written on the business in the Top 20 series. In this I mentioned that it was looking to be a potentially attractive proposition. Since then the market capitalisation of the business has gone up by circa. 15% so we thought it may be pertinent to see whether it remained a buy still. The questions posed related to where TLS is going in terms of the bottom line, we do prefer some vision for the future of the businesses we invest in after all. Below are the CEO’s recent comments on what he sees going forward:
“Thank you for your questions. FY21 was an inflection point for the financial performance of our business, with strong momentum in the second half leading to sequential growth in underlying EBITDA. We have confidence this momentum will continue, and we have provided guidance for FY22 underlying EBITDA in the range of $7.0-7.3b which represents mid to high single digit growth. There are three key drivers – (1) Mobile, for which we expect to see ongoing service revenue and EBITDA growth, (2) Enterprise, for which we expect revenue and EBITDA growth in FY22 across mobile, fixed and international, and (3) productivity, with a $430m cost out target for FY22. We are also focused on diversifying our growth across other verticals including in Energy and Health, while our investment in Foxtel is well positioned for the future following recent exceptional subscriber growth. We will communicate our strategy for the future at our Investor Day on 16 September 2021. This strategy will be firmly focused on continuing to improve customer experience, driving growth and leveraging the foundation and capabilities we have built through our T22 strategy over the last three years.”
Not bad Telstra, not bad.
Disclaimer: ING, MND & TLS are currently not positions in the TAMIM portfolio’s
This week we discuss a hidden gem on the ASX and one which we believe has the ultimate investment exposure in a Covid world. With the company only listing three months ago it is yet to receive much attention from fund managers and brokers, yet it is highly profitable and on an upgrade cycle. Find out which stock below.
Author: Ron Shamgar
Australian Clinical Labs (ACL.ASX) is the third largest pathology provider in Australia. The pathology market is worth over $6bn annually and 80% of revenues are dominated by three main players: Sonic Healthcare (SHL.ASX), Healius (HLS.ASX) and ACL – with 16% market share. The industry is growing at approximately 5.4% per annum but Covid PCR based testing has added another layer of substantial and lucrative revenues.
Source: Goldman Sachs Equity Research
Now whether Australia reaches 80% or 100% vaccination rates, or whether we are in and out of lockdowns or completely open our borders – we don’t believe it matters for testing requirements. Whatever your stance on the situation, Australia’s Covid strategies and responses are fixated on case numbers. This means that, for better or worse, testing volumes should continue to stay elevated for a couple of years to come.
What gives us confidence in this statement is the high levels of Covid cases overseas, especially in countries where vaccination rates are high. Ongoing testing will be required for travel purposes, work related requirements, healthcare and staying on top of different strains of the virus that will undoubtedly evolve over time. More importantly, alternative antibody (antigen) testing methods so far appear to be unreliable in replacing PCR based methods. ACL are currently serving over ninety hospitals and are also running thirty specialist skin cancer clinics across Australia which are responsible for diagnosing over 15% of all reported melanomas. Hence ACL profits are sustainable for now.
Source: Goldman Sachs Equity Research
The company has significant momentum and is in the midst of a strong upgrade cycle that we believe the market is currently overlooking. FY21 prospectus forecasts were beaten by 5% on revenues (to $674m) and were over 20% ahead in the NPAT line (to $89m). Free cash flows are strong and the balance sheet ended the period with low levels of net debt ($65m).
Source: ACL company filings
All this should allow ACL to continue to make acquisitions, especially in NSW and QLD where ACL’s market share is still quite low. Unlike their larger peers, ACL should be able to make smaller acquisitions that make a meaningful impact on their bottom line. ACL’s past acquisitions have increased their presence throughout Australia and have provided significant synergies for the company by reducing operating costs and improving EBITDA margins. Watch this space.
The momentum behind the business was evident with 1H22 guidance upgraded significantly from prospectus forecasts. Revenues are now 22% ahead of the previous forecast and NPAT is a whopping 130% ahead at $53m. To put this in perspective, analysts previously had ACL earning $53m for the whole of FY22. Dividends are expected to be paid at 60%+ of profits, placing the stock on a 6%+ fully franked yield.
ACL has also invested significantly in their in-house tech and operates a national unified pathology system that allows the majority of tests, clinicians and laboratories to operate as one laboratory across the country. ACL’s unified pathology system enables operational benefits which include improved turnaround times and ability to handle demand peaks, national benchmarking to drive performance improvement and efficiencies and share innovations. Their system is a competitive advantage and has been a key factor in their ongoing and pivotal role in Australia’s Covid response. This system and the advantages it brings will serve them well if and when there is a decline in Covid testing.
Source: ACL company filings
Last year we successfully (and rather profitably) rode the wave of Covid winners in e-commerce and BNPL stocks. We see ACL as a similar beneficiary but on a more long term and sustainable level. Any slowdown in Covid testing should be replaced by increase in non-Covid business/testing resuming.
Source: ACL company filings
With SHL and HLS trading on 14-19x PE multiples, we see ACL – currently at 9x PE – as significantly undervalued. We believe that management’s FY22 guidance is conservative as was their FY21 guidance. They are assuming a sharp deceleration in test volumes and, as we said above, we don’t believe it will be quite so sudden. On the back of the conservative forecasts, we expect further upgrades through the year and further acquisitions to drive a rerate. An ASX300 index inclusion is also potentially on the cards. Our valuation is $6.00+ and ACL is currently one of our top holdings in both the Australia All Cap and Australia Small Cap Income portfolios.
Disclaimer:ACL is currently held in TAMIM Australian equity portfolios.
This week we discuss a hidden gem on the ASX and one which we believe has the ultimate investment exposure in a Covid world. With the company only listing three months ago it is yet to receive much attention from fund managers and brokers, yet it is highly profitable and on an upgrade cycle. Find out which stock below.
Author: Ron Shamgar
Australian Clinical Labs (ACL.ASX) is the third largest pathology provider in Australia. The pathology market is worth over $6bn annually and 80% of revenues are dominated by three main players: Sonic Healthcare (SHL.ASX), Healius (HLS.ASX) and ACL – with 16% market share. The industry is growing at approximately 5.4% per annum but Covid PCR based testing has added another layer of substantial and lucrative revenues.
Source: Goldman Sachs Equity Research
Now whether Australia reaches 80% or 100% vaccination rates, or whether we are in and out of lockdowns or completely open our borders – we don’t believe it matters for testing requirements. Whatever your stance on the situation, Australia’s Covid strategies and responses are fixated on case numbers. This means that, for better or worse, testing volumes should continue to stay elevated for a couple of years to come.
What gives us confidence in this statement is the high levels of Covid cases overseas, especially in countries where vaccination rates are high. Ongoing testing will be required for travel purposes, work related requirements, healthcare and staying on top of different strains of the virus that will undoubtedly evolve over time. More importantly, alternative antibody (antigen) testing methods so far appear to be unreliable in replacing PCR based methods. ACL are currently serving over ninety hospitals and are also running thirty specialist skin cancer clinics across Australia which are responsible for diagnosing over 15% of all reported melanomas. Hence ACL profits are sustainable for now.
Source: Goldman Sachs Equity Research
The company has significant momentum and is in the midst of a strong upgrade cycle that we believe the market is currently overlooking. FY21 prospectus forecasts were beaten by 5% on revenues (to $674m) and were over 20% ahead in the NPAT line (to $89m). Free cash flows are strong and the balance sheet ended the period with low levels of net debt ($65m).
Source: ACL company filings
All this should allow ACL to continue to make acquisitions, especially in NSW and QLD where ACL’s market share is still quite low. Unlike their larger peers, ACL should be able to make smaller acquisitions that make a meaningful impact on their bottom line. ACL’s past acquisitions have increased their presence throughout Australia and have provided significant synergies for the company by reducing operating costs and improving EBITDA margins. Watch this space.
The momentum behind the business was evident with 1H22 guidance upgraded significantly from prospectus forecasts. Revenues are now 22% ahead of the previous forecast and NPAT is a whopping 130% ahead at $53m. To put this in perspective, analysts previously had ACL earning $53m for the whole of FY22. Dividends are expected to be paid at 60%+ of profits, placing the stock on a 6%+ fully franked yield.
ACL has also invested significantly in their in-house tech and operates a national unified pathology system that allows the majority of tests, clinicians and laboratories to operate as one laboratory across the country. ACL’s unified pathology system enables operational benefits which include improved turnaround times and ability to handle demand peaks, national benchmarking to drive performance improvement and efficiencies and share innovations. Their system is a competitive advantage and has been a key factor in their ongoing and pivotal role in Australia’s Covid response. This system and the advantages it brings will serve them well if and when there is a decline in Covid testing.
Source: ACL company filings
Last year we successfully (and rather profitably) rode the wave of Covid winners in e-commerce and BNPL stocks. We see ACL as a similar beneficiary but on a more long term and sustainable level. Any slowdown in Covid testing should be replaced by increase in non-Covid business/testing resuming.
Source: ACL company filings
With SHL and HLS trading on 14-19x PE multiples, we see ACL – currently at 9x PE – as significantly undervalued. We believe that management’s FY22 guidance is conservative as was their FY21 guidance. They are assuming a sharp deceleration in test volumes and, as we said above, we don’t believe it will be quite so sudden. On the back of the conservative forecasts, we expect further upgrades through the year and further acquisitions to drive a rerate. An ASX300 index inclusion is also potentially on the cards. Our valuation is $6.00+ and ACL is currently one of our top holdings in both the Australia All Cap and Australia Small Cap Income portfolios.
Disclaimer:ACL is currently held in TAMIM Australian equity portfolios.
Our friends at Merricks Capital, an allocation in the TAMIM Credit portfolio, take a look at changing shopping and consumption habits in the wake of COVID-19. An important consideration for anyone with exposure, equities or otherwise, to these sectors.
This article was originally distributed on 20 August 2021 and has been reproduced in part with the permission of Merricks Capital.
Changing shopping and food consumption patterns have occurred as a result of the COVID pandemic and the resulting lockdowns. Some of these trends have normalised but there is likely to be a more permanent shift in some areas of food demand.
These structural shifts have implications for the entire agriculture supply chain, and we are seeing increasing investment in technology and infrastructure from some of our borrowers and the larger supermarket chains to support this demand.
Merricks Capital recently spoke with one of our borrowers, who arguably produces some of Australia’s best Wagyu beef, about the impact of the stand still in the restaurant and hospitality supply chain.
In summary the “dine in” distribution channels have come to a halt but the increase in demand from consumers for high end food product through home delivery and grocery channels has been significant.
We are currently reviewing several opportunities across the food supply chain that will support “the premiumisation” of consumers “in home” demand.
The increased investment in the industry and ongoing changes in food consumption trends will not only ensure the continued performance of our existing investments in the agriculture industry, but they will result in an increasing level and diversity of opportunity going forward.
As part of its annual results presentation this week, Coles provided an update on the impact of COVID on trends in food demand and consumption.
Sales in its supermarket division rose 2.5% on a comparable basis over FY21, and by 8.4% over 2 years. While consumer behaviours began to normalise at the end of the third quarter and into the fourth quarter, increased in-home consumption as a result of COVID-19 positively impacted sales revenue growth throughout the year.
Normalising consumer behaviours in the fourth quarter included the return of Sundays as the largest trading day of the week, customers shopping more frequently, and transaction trends improving with growth in the convenience, food-to-go and impulse categories. While basket size moderated, they remain above pre-COVID 19 levels.
Coles noted inflation in the fresh food segment (supermarket price deflation ex tobacco and fresh food of 0.8% compared to total price inflation of 0.8%) highlighting red meat as a source of price inflation due to elevated livestock prices. This is consistent with ABS data which showed price inflation over the June quarter for vegetables (+5.5%) and fruit (+4.7%), partly driven by a shortage of pickers and extreme rainfall on the east coast of Australia. Beef and veal prices rose 3.6% with farmers continuing to re-build herds, reducing meat supply. Food prices overall rose 0.7% over the financial year.
Coles and Woolworths control around 70% of the grocery market and are central to Australia’s agricultural sector. Trends in supermarket food demand can have important implications across the entire agriculture supply chain.
Around 31% of fruit and nut production is exported (compared to 71% of total agricultural production) and these industries are particularly dependent on trends in the domestic market.
Separately, food price inflation is a positive for the industry when it is accompanied by higher margins for farmers and food manufactures, ensuring the continued profitability of the sector, and our borrowers.
The Tamim Credit fund through its investment into Merricks, has exposure to the agriculture sector including the supply chain. These investments are across quality assets that will benefit from the increased incidence of at-home food preparation and consumption, including the demand for fresh pre-prepared and convenience meals, as well as higher prices.
The “premiumisation” of home cooking is a particularly interesting trend. Feedback from our wagyu production business, for example, indicates that wholesale (restaurant) demand has been largely displaced by retail and home delivery of premium beef product, and this has resulted in orders and pricing remaining steady.
Both Woolworths and Coles have indicated a focus on investing in technology, including in their online capabilities and supply chain modernisation programs. These capital expenditure plans are evidence of the commitment from the largest participants in the market to the delivery of world-class technology solutions to improve efficiencies, customer experience and a secure food supply.
The changing landscape in food demand and consumption means that food production businesses will need to become more efficient and less reliant on seasonal labour. This is driving the need for capital investment which is providing a range of attractive lending opportunities in the sector.
The impact of COVID-related lockdowns on agriculture markets is complex. Low population growth will weigh on overall demand, but the shifting dynamics of that demand – from restaurants and take-away to home preparation and consumption – and the investment in technology and modernisation, will continue to have implications across the agriculture supply chain. These changes will ensure a continuing flow of opportunities across a diversified portfolio of assets, which will provide investors with attractive risk-adjusted investment returns.
Disclaimer: There is currently an allocation to Merricks Capital in the TAMIM Fund: Credit portfolio. A portfolio investing into private debt and other credit opportunities with the aim of generating a steady, consistent interest income stream for investors whilst at the same time seeking to preserve capital.
This week we continue our look at dividend yielding stocks with two companies that make reasonable investment propositions. One rather unloved by the market, Aurizon Holdings Ltd (AZJ.ASX), and the other reasonably fair value, APA Group (APA.ASX), but both offering steady long-term dividend streams.
Aurizon Holdings (AZJ.ASX)
Floated in 2010, Aurizon has certainly seen ups and downs over the past decade. Before we get to the details, a brief overview of the company. Originally known as QR National, the company was established in 2004 bringing together Queensland Rail’s coal, bulk and containerised businesses. It grew by acquisitions over the following decade, expanding nationally and taking over Australian Rail Group and CRT, giving it a footprint across NSW, Victoria and WA. To put it simply, the company provides design, construction, overhaul, maintenance and management services to the mining industry with the bread butter remaining the Central Queensland Coal Network (CQCN). Given the loss of appetite with regards to coal and fossil fuels, the business has seen significant headwinds since IPO. With the likely long-term decline in its traditional business, it may seem surprising to many that we would even consider it. However, it must be viewed as a business in transition.
While we see significant declines in the market for thermal coal, we also see continued demand for metallurgical and coking coal, a key ingredient in the manufacture of steel. This is one segment that is likely to continue to see tailwinds given the impetus for spending on infrastructure globally. If spot prices are anything to go by, close to doubling in the past year, we are seeing significant pockets of value in the space. In fact, the company expects haulage volumes for 2021 to increase by 5%. Drilling down further, while we have seen flatlining or declines in crude steel production in China we are likely to see this cushioned by increases in India and across Asia (including Japan) as nations embark upon upgrading their own infrastructure. In our view, it is rather telling that the business extended its contracts with its biggest customers, including Glencore (GLEN.LON), Anglo American (AAL.LON) and New Hope (NHC.ASX).
Author: Sid Ruttala
For those still not convinced, there is a clear strategy from management that takes into account the long-term structural headwinds facing the industry. This includes declines in the demand for thermal coal with a target to reduce exposure to thermal coal to less than 20% of Above Rail revenues by 2030. This is a more than rational business decision given that the world will still require Thermal during the ongoing transition period. Look to the recent example of China, a situation which has resulted in spot prices sky-rocketing to $170 USD/Tonne (doubled on a 12-month basis). Despite the government’s adamant assertion of zero-emission targets, a heat wave in Zhejiang, Jiangsu and Guangdong (her biggest industrial provinces) saw output pushed higher and bottlenecks during peak demand. It is also quite telling that policy makers have restarted production in the Shanxi and Xinjiang provinces (a region prone to flooding, by the way). Suffice it to say, these bottlenecks mean that the AZJ’s 20% target may not be as much of a liability as we still see the economics making sense over the medium-term.
Moving away from coal, Aurizon continues to focus on its bulk business which has seen significantly higher volumes. Customers here include the likes of South32 (S32.ASX), CBH Resources and mineral resources with exposures split nicely across iron ore, base metals and agriculture (i.e. grain). All exposures that we continue to see demand for within the Green Economy.
So, why does it make sense?
We feel that it currently trades at the valuation of a pure fossil fuels play with little thought given to the active transition occurring. Management has a clear strategy for diversifying the business substantially through value add, as is indicated by the purchase of Newcastle and Townsville shipping facilities, which adds storage and ship loading capabilities along with potential for near-term organic growth prospects in the lithium and mineral sands space. Moreover the nature of the businesses, including long-contracted revenues (insulates the investor from fluctuations within the day-to-day gyrations of the spot market) and capital intensity (creates high barriers to entry) make it a reasonable risk-reward proposition.
With that, let’s quickly get to the numbers. EBITDA at $1.482bn AUD, statutory NPAT at $607m AUD, and FCF (Free Cash Flow) of $734m AUD. Interestingly, management’s guidance (and our expectations) are that we are likely to see $ 1.5bn for EBITDA. Granted, this is on the upper end of the guidance but we see no reason for this not to be the case.
Red Flags & Risks: This remains an annuity-like return stream for the discerning investor but the risk for capex blowouts remains the same as well as shorter term volatility within the coal and minerals market. Non-growth capex guidance for FY22 came in at $475-525m, however the question mark remains around the capex required for growth in the bulk side of the business.
In addition, China’s confrontational approach to Australian coal exports continue to be a headwind for the markets though this has been priced in and the company has made some headway in outlining a clear strategy for alternative markets (i.e. India and South East Asia).
Dividend Yield: A stellar 7.2% and we see this continuing to be the case over the long-term on the balance of probabilities.
APA Group (APA.ASX)
Despite this series mostly focusing on unloved businesses, APA came across our radar when they outlined their strategy for the next generation of growth in renewables and expansion into the lucrative US market.
First, a brief history and overview.
Listed in 2000, the Australian Pipeline Trust is an offshoot of AGL (AGL.ASX) starting with an interest in 7,000km of transmission pipelines. APA today owns and operates over 15,000km of pipelines along with 27,000km in Gas Distribution Mains as well as storage facilities, power stations, wind and solar farms. It accounts for the transportation of a quarter of gas used in Australia. Investors in the parent must be thinking of the irony. APA with a market capitalisation of $11.5bn AUD and AGL with its market capitalisation of $4.5bn AUD, a clear showcase of value creation vs. destruction by management teams. Nevertheless, we shall stop there given that we’ve previously posited that AGL looks relatively cheap.
We see significant tailwinds for the company going forward as the domestic market transitions toward renewables and energy security. Natural gas, in our view, will continue to be a key component of the energy mix going forward. Also telling is the continued expansion domestically of the East Coast gas grid in the Southern states, despite increased regulatory scrutiny on the domestic gas market. The transport agreement with Origin (ORG.ASX) has substantially de-risked this but the very manner in which management has gone about building the business and opportunity set is a great start. So, what does this entail? Firstly, it upgrades both the South West QLD pipeline and Moomba Sydney Pipeline and enables an 25% capacity increase via compression (as opposed to building new pipelines) with Origin coming in to take some of the increased capacity and locking in incremental revenue of $190m AUD over a 3-year period for the privilege of doing so.
We see similar capacity improvements across APA’s footprint along with continued optimisation of existing infrastructure. While many in the industry have faced significant headwinds due to regulatory intervention, APA’s astute management has found themselves continuing to operate in the overlooked niches (i.e. less regulated) where they can take advantage of asymmetric information in negotiation. On the flip-side, while it is likely that there will be additional construction of new import terminals by retailers, a policy likely to be encouraged by governments seeking to increase competition in the domestic market APA’s pipeline footprint makes it an attractive and cheaper alternative at least in the short-run.
Looking to the future, management’s vision is what we find to be the most attractive proposition. First, the potential expansion of the domestic footprint looking to capitalise on the close to $68bn AUD opportunity set that is Australia’s transition to renewables by 2040. Management estimates that pipelines and associated infrastructure is worth about $8bn, $40bn AUD in generation and storage and $20bn AUD in transmission. We see APA as a leading contender for the lion’s share of the pipelines and associated infrastructure with management potentially developing additional capabilities in storage and transmission. That being said, they may not be able to ascertain outsized returns outside the core capabilities during the initial stages. We also see the business as more likely to focus on wind generation as opposed to solar in order to prevent downward pressure on prices during the day.
Source: apa.com.au
Looking beyond Australia, management has indicated a desire to enter the US market where a significantly larger $2.5tn USD opportunity is up for grabs to 2040. This includes the potential for buying out existing pipelines or a utility company during the initial stages. With the enormity of the transition taking place, they may be able to buy out a non-core asset from an energy company before expanding further. While there is obviously risk there, we feel the APA has the track-record and the expertise to move into the space. In addition to looking at diversifying the pipeline usage, one interesting idea floated was the potential to use the existing pipeline infrastructure, initially the Parmelia Gas Pipeline, for the transportation of hydrogen with the potential to export at a later date.
With that, let’s get to the numbers. First half EBITDA came in at $823m AUD, down slightly (-2%) but expected due to Covid, and, concerning energy consumption for the full year, our view is that the figures will come in at a slight decline of -1.2% for the full year ($1.6bn AUD). NPAT at $290m AUD, an estimate and based on management guidance.
A fairly valued stock but still a reasonable buy, a strong well run defensive investment with growth attributes.
Red Flags & Risks: The biggest risk remains the aggressive expansion strategy that management is likely to implement (also happens to be the most attractive attribute). Debt is likely to be on the upper end of the metric allowances for a BBB/Baa2 credit rating should they proceed with an acquisition and, while the regulated return on equity allowances in the US should they proceed remains an attractive 10%, the risk of overpaying especially given the environment remains.
Over the long-run, an increasingly confrontational regulatory environment in the Australian market remains a threat along with increased competition.